**Core Concept**
Histamine H3 receptors play a crucial role in regulating arousal and sleep-wake cycles. Inverse agonists at these receptors can increase histamine release and wakefulness, making them potential therapeutic agents for treating narcolepsy.

**Why the Correct Answer is Right**
Pitolisant is a selective histamine H3 receptor inverse agonist that increases histamine release and wakefulness. By binding to the H3 receptor, pitolisant reduces its inhibitory effects on histamine release, leading to increased histamine levels in the brain and improved wakefulness. This mechanism is particularly useful in treating narcolepsy, a disorder characterized by excessive daytime sleepiness.

**Why Each Wrong Option is Incorrect**
**Option A:** Dexmedetomidine is an alpha-2 adrenergic receptor agonist, not an inverse agonist at H3 receptors. It is used for sedation and has a different mechanism of action compared to pitolisant.
**Option C:** Icatibant is an antagonist of the bradykinin B2 receptor, used for treating hereditary angioedema. It has no relation to H3 receptors or narcolepsy treatment.
**Option D:** Secukinumab is an interleukin-17A inhibitor, used for treating psoriasis and other inflammatory conditions. It has no mechanism of action involving H3 receptors or wakefulness regulation.

**Clinical Pearl / High-Yield Fact**
Pitolisant's unique mechanism of action as an H3 receptor inverse agonist makes it a valuable addition to the treatment armamentarium for narcolepsy. Remember that inverse agonists can have different effects compared to antagonists or agonists at the same receptor.

**✓ Correct Answer: B. Pitolisant**